OrbiMed’s IGM Biosciences IGMS Stock Holding History

OrbiMed’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-80,760	Closed	-$5.89M	–	151
2020 Q2	$5.89M	Hold	80,760	–	–	0.08%	115
2020 Q1	$4.54M	Buy	+80,760	New	+$3.54M	0.08%	110

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed's IGMS Position: Q3 2020 in Review

OrbiMed sold out of IGM Biosciences (IGMS) in Q3 2020, closing a stake of 80,760 shares — an estimated $5.89M sold.

OrbiMed first reported a position in IGMS in Q1 2020 and held it in 2 quarters. The position peaked at $5.89M in Q2 2020. 91 funds tracked by Wall St. Rank hold IGMS as of Q3 2020.

OrbiMed reported no remaining IGM Biosciences position as of Q3 2020 after selling out during the quarter.
OrbiMed sold 80,760 IGM Biosciences shares in Q3 2020, an estimated $5.89M.
OrbiMed first reported a position in IGM Biosciences in Q1 2020 and held it in 2 quarters.
OrbiMed's IGM Biosciences position peaked at $5.89M in Q2 2020.
91 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.